News

The partnership between Arkstone Medical Solutions and Dendi represents a significant step forward in providing healthcare providers with the tools and technologies they need to make informed clinical decisions.

The NIH has been collecting lab result isolate data for decades, compiling information about the prevalence of antimicrobial resistance genes in specific organisms.

Now, providers have access to detailed and dynamic renal and hepatic dosing adjustments for any treatment recommendations provided.

Many healthcare providers treating infections in a pregnant patient have difficulty finding the best treatment, while also taking into consideration an antimicrobial that will have the lowest risk to the fetus.

Ovation LIMS/LIS enables prominent molecular diagnostic laboratories to provide comprehensive test results to thousands of clinicians nationwide. Now, these labs can deliver the Arkstone OneChoice report combined with the patient’s detected pathogens and antibiotic resistance genes outlined in the infectious disease laboratory results.

MedsMatrix expands on OneChoice by giving the provider a clear understanding of what different treatment options are, and even some insight into how the OneChoice decision engine came to its conclusions

Dr. Juan Carlos Gómez de la Torre Pretell, founder of the Peruvian Institute of Molecular Biology, will be an integral part of Arkstone’s advancements in the use of artificial intelligence to democratize infectious disease expertise and increase antibiotic stewardship.

The Antimicrobial Stewardship Monthly Report includes month-to-month tracking of infections from many different sources, including respiratory, wound, urine, and GI. The report breaks down the most common types of infections and resistance genes and analyzes this data so that trends are easily visible, allowing for the implementation of proactive surveillance and infection control policies.